Delray Medical Center Is First Hospital in Region Offering INSIGHTEC™

New Incisionless RX Option for Parkinson’s & Essential Tremor Patients

Delray Medical Center is the first hospital in the region to offer a new scalpel-free treatment for essential tremor and medication-refractory tremor-dominant Parkinson’s disease.

MR-guided focused ultrasound by INSIGHTEC™, uses sound wave energy to treat brain tissue at the source of the tremor.  No surgical incision or anesthesia is necessary, and patients may experience immediate and significant reduction in their hand tremors, giving them a chance to get back to their daily activities.

“This technology is a game changer in our community and for those seeking the very latest in cutting edge technology for neurologic care of Parkinson’s disease,” said Dr. Lloyd Zucker, chief of neurosurgery at Delray Medical Center.
“This technology is a game-changer in our community and for those seeking the very latest in cutting edge technology for neurologic care of Parkinson’s disease,” said Dr. Lloyd Zucker, chief of neurosurgery at Delray Medical Center. “The future is bright for those who may be stricken with this neurological disease, as we can care for these patients with this new innovative solution to treat tremors.”

MR-guided focused ultrasound combines two technologies, magnetic resonance imaging (MRI), which pinpoints the exact location in the brain responsible for the tremor, and ultrasound, which precisely delivers over 1,000 highly focused beams of acoustic energy at that exact location without damaging any surrounding brain tissue.

Some of the benefits to this technology include:

  • No surgical incisions resulting in reduced risk of infection.
  • Quicker recovery time with no surgical incision, allowing a return to daily activities within days.
  • Performed as an outpatient procedure – most patients go home within 23 hours.
  • Immediate and significant reduction in hand tremors.
  • Treatment has minimum side effects.

“Delray Medical Center is proud to be the first hospital in the region to offer this new technology to the community who are in need of top notch neurologic care,” said Dr. Arif Dalvi, medical director of the movement disorder center for Delray Medical Center.  “We continue to bring breakthrough treatments to our hospital so patients can find quality care close to home.”

Delray Medical Center has the advanced technology and services to help with any of your neurological issues.  As a member of the Advanced Neuroscience Network, an integrated delivery system of medical professionals and hospitals focused on offering a full continuum of neurological care throughout South Florida, we focus on everything from prevention and diagnosis to treatment and rehabilitation.  For more information about our services go to our website at www.delraymedicalctr.com or call 561-498-4440.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version